Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deleobuvir + Faldaprevir + Ribavirin vs Telaprevir in HCV GT1b
NCT01858961Phase 3Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- May 2013
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of deleobuvir in chronic hepatitis C (CHC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Sustained Virologic Response at Week 12. Planned start May 2013; status: withdrawn.
02
Drugs
deleobuvir
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on NCT01858961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01858961.